Antibiotics

Study finds antibiotic use alters native gut bacteria that normally compete with C. diff for nutrients.

In case you missed them, we've compiled the top five infectious disease articles from this past week.

In a new international study, a team of European authors says that antibiotic use for preventative purposes is too high in pediatric hospitals, prompting a call for better antibiotic stewardship efforts.

The first case of gonorrhea resistant to available first-line antibiotics has been reported in the United Kingdom.

Coordinated efforts with health departments at the local and state levels are protecting individuals by stopping the spread of new and unusual types of antibiotic resistance throughout the United States.

Here’s what needs to be addressed in order to make real progress in the fight against antimicrobial resistance, according to Dr. Ramanan Laxminarayan, PhD, Center for Disease Dynamics, Economics, & Policy.

In case you missed them, we've compiled the top 5 articles from this past week.

Antibiotic resistance is highly concerning to researchers, but a team of researchers have identified new synthetic antibiotics with the potential to kill aggressive bacteria.

SHEA and APIC have declared infection control programs as critical components of antimicrobial stewardship programs—are you including them at your institution?

Based on current projections, antibiotic consumption could increase by as much as 200% by 2030.

Preliminary research suggests that women who take antibiotics for long periods of time in late adulthood may be at increased risk of death from heart disease and other causes.

Research presented at the 47th Critical Care Congress reveals that PCT-guided antibiotic cessation in critically ill patients resulted in reduced mortality.

Marin H. Kollef, MD, discusses the strongest approach for treating Pseudomonas infections.

Scientists from the NIH and Rutgers New Jersey Medical School are in the process of developing a promising alternative to antibiotic treatments for multidrug-resistant Klebsiella pneumoniae bacteria.

CARB-X, the international partnership between governmental and charitable groups in the United States and the United Kingdom, has announced new funding for the development of new antibiotics to fight drug-resistant bacteria.

High prescribing continues despite the fact that heavy use of these agents can facilitate the development of multidrug-resistant bacteria and tendon, muscle, joint, and central nervous system damage.